Suloctidil HCl | CAS#54767-71-4 | peripheral vasodilator

MedKoo Cat#: 527697 | Name: Suloctidil HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Suloctidil HCl is a peripheral vasodilator.

Chemical Structure

Suloctidil HCl

CAS#54767-71-4

Theoretical Analysis

MedKoo Cat#: 527697

Name: Suloctidil HCl

CAS#: 54767-71-4

Chemical Formula: C20H36ClNOS

Exact Mass: 373.2206

Molecular Weight: 374.02

Elemental Analysis: C, 64.23; H, 9.70; Cl, 9.48; N, 3.74; O, 4.28; S, 8.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Suloctidil HCl

IUPAC/Chemical Name

(1R*,2S*)-2-(Octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol hydrochloride

InChi Key

JRJJHIUHSILDOH-ZHXLSBKVSA-N

InChi Code

InChI=1S/C20H35NOS.ClH/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3;/h11-14,16-17,20-22H,5-10,15H2,1-4H3;1H/t17-,20-;/m0./s1

SMILES Code

C[C@H](NCCCCCCCC)[C@@H](C1=CC=C(SC(C)C)C=C1)O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 374.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zeng B, Li J, Wang Y, Chen P, Wang X, Cui J, Liu L, Hu X, Cao Q, Xiao Y, Dong J, Sun Y, Zhou Y. In vitro and in vivo effects of suloctidil on growth and biofilm formation of the opportunistic fungus Candida albicans. Oncotarget. 2017 Jul 25;8(41):69972-69982. doi: 10.18632/oncotarget.19542. eCollection 2017 Sep 19. PubMed PMID: 29050256; PubMed Central PMCID: PMC5642531. 2: Butts A, DiDone L, Koselny K, Baxter BK, Chabrier-Rosello Y, Wellington M, Krysan DJ. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot Cell. 2013 Feb;12(2):278-87. doi: 10.1128/EC.00314-12. Epub 2012 Dec 14. PubMed PMID: 23243064; PubMed Central PMCID: PMC3571299. 3: Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002071. doi: 10.1002/14651858.CD002071.pub3. Review. PubMed PMID: 22895926. 4: Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem. 2008 Jan 24;51(2):219-37. Epub 2007 Nov 21. PubMed PMID: 18027916. 5: Piccioni F, Roman BR, Fischbeck KH, Taylor JP. A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum Mol Genet. 2004 Feb 15;13(4):437-46. Epub 2004 Jan 6. PubMed PMID: 14709594. 6: Lapathitis G, Kotyk A. Two forms of yeast plasma membrane H(+)-ATPase: comparison of yield and effects of inhibitors. Folia Microbiol (Praha). 2000;45(3):221-3. PubMed PMID: 11271804. 7: Kotyk A, Lapathitis G, Krenková S. Glucose- and K(+)-induced acidification in different yeast species. Folia Microbiol (Praha). 1999;44(3):295-8. PubMed PMID: 10664885. 8: Lapathitis G, Kotyk A. Different sources of acidity in glucose-elicited extracellular acidification in the yeast Saccharomyces cerevisiae. Biochem Mol Biol Int. 1998 Dec;46(5):973-8. PubMed PMID: 9861451. 9: Itil TM, Eralp E, Ahmed I, Kunitz A, Itil KZ. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull. 1998;34(3):391-7. PubMed PMID: 9803773. 10: Cimprich P, Slavík J, Kotyk A. Distribution of individual cytoplasmic pH values in a population of the yeast Saccharomyces cerevisiae. FEMS Microbiol Lett. 1995 Aug 1;130(2-3):245-51. PubMed PMID: 7649447. 11: Verry M, Panak E, Cazenave JP. Antiplatelet therapy in the prevention of ischaemic stroke. Nouv Rev Fr Hematol. 1994 Jun;36(3):213-28. Review. PubMed PMID: 7971242. 12: Kotyk A. Dependence of the kinetics of secondary active transports in yeast on H(+)-ATPase acidification. J Membr Biol. 1994 Feb;138(1):29-35. PubMed PMID: 8189429. 13: Chauvet-Monges AM, Faure R, Crevat A. 1H-NMR study of suloctidil-A23187 calcium ionophore interaction. Chem Biol Interact. 1993 Feb;86(2):163-9. PubMed PMID: 8383582. 14: Tkaczewski W, Buczyński A, Dziedziczak-Buczyńska M, Wachowicz B, Kedziora J. [The effect of suloctidil and acetylsalicylic acid on eicosanoid synthesis in human platelets]. Pol Tyg Lek. 1992 Oct 19-26;47(42-43):970-1. Polish. PubMed PMID: 1338656. 15: Kotyk A, Dvoráková M. Are proton symports in yeast directly linked to H(+)-ATPase acidification? Biochim Biophys Acta. 1992 Mar 2;1104(2):293-8. PubMed PMID: 1347702. 16: Barnett HJ. Clinical trials in stroke prevention. Arzneimittelforschung. 1991 Mar;41(3A):340-4. Review. PubMed PMID: 1859505. 17: De Paermentier F, Heuschling P, Knoops B, Janssens De Varebeke P, Pauwels G, Laszlo De Kaszon-Jakabfalva C, Van den Bosch De Aguilar P. Suloctidil increases the rat brain cortex microvascular regeneration after a lesion. Life Sci. 1989;44(1):41-7. PubMed PMID: 2464117. 18: Chung MW, Komorowski RA, Varma RR. Suloctidil-induced hepatotoxicity. Gastroenterology. 1988 Aug;95(2):490-1. PubMed PMID: 2839389. 19: Valenzuela Miranda C, Aller Reyero MA, Arias Pérez J, Alsasua del Valle A, Arias Pérez JL, Rodríguez Sánchez JC, Durán Sacristán H. [Suloctidil decreases the serotonin concentration in the brain stem of rats with a portacaval shunt]. Rev Esp Enferm Apar Dig. 1988 May;73(5 Pt 2):547-52. Spanish. PubMed PMID: 2845525. 20: Imaizumi S, Suzuki J, Kinouchi H, Yoshimoto T. Superior protective effects of phenytoin against hypoxia in a pharmacological screening test. Neurol Res. 1988 Mar;10(1):18-24. PubMed PMID: 2899850.